Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Eric Dein ericdeinmd
3 years 1 month ago
Ab0411 #ACR22 Bimekizumab in AS
P3 24 wk PBO control study BE-MOBILE 2
221 BKZ, 111 PBO
Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001
Efficacy in both TNF naive and TNF failure pts
Wk 24: 1/2 pts has ASDAS<2.1
Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%)
@Rheumnow https://t.co/R1ieW0FB6m
Richard Conway RichardPAConway
3 years 1 month ago
Mathew et al. Combination biologics from MarketScan. Combination less likely to have ER visit in 180 days 17% vs 23% @RheumNow #ACR22 Abstr#0768 https://t.co/Y880qDXMow https://t.co/gOH2Zlt6UV
Aurelie Najm AurelieRheumo
3 years 1 month ago
CASIPSA study: retro CT SIJ analysis 48 PsA & age/sex matched ctrls.
JSN, erosion, sclerosis in 1/3 pts w/ peripheral & 1/3 pts w/ axial disease.
PsA > erosions, no diff in other parameters: lack of power or true absence of diff?
https://t.co/CR0LymrinT
Abs#1012 #ACR22 @Rheumnow https://t.co/akYYqbIFNx
Richard Conway RichardPAConway
3 years 1 month ago
Wang @zach_wallace_md et al. Machine learning can accurately classify clinical note sections as reflecting a diagnosis of AAV. As a machine learning sceptic, data like this helps (slowly) convert me. @RheumNow #ACR22 Abstr#0700 https://t.co/qbq9j9XzXG https://t.co/8iNJElI2vJ
Mike Putman EBRheum
3 years 1 month ago
I typically do not use mepolizumab for "vasculitic" EGPA --> recent ACR/VF guidelines agreed
Interesting study @TerrierBen suggests benefit regardless of ANCA, BVAS, VDI
Have others been using in this context or seen similar?
#ACR22 @RheumNow #ACRBest #1075 https://t.co/C6isdSn2eI
Dr. John Cush RheumNow
3 years 1 month ago
Are we really treating Psoriatic disease if we only address active disease domains and T2T? #ACR22
https://t.co/D3F5EzLfeP https://t.co/TO3GyZA6Lb
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#1654 Press Release #lupus. A cohort study using case-crossover design showed that HCQ dose =<5mg/kg actual body weight OR <400mg/day were associated with increased risk of severe #SLE flare requiring hospitalisation. Need to review Guidelines on HCQ dose @RheumNow https://t.co/5mMh7g6wcA
Janet Pope Janetbirdope
3 years 1 month ago
Toxic granules in blood vessels may damage vasculature and cause fibrosis around vessels. ‘Occult vascular disease occurs in #scleroderma, don’t forget about it’ says Wigley at Hench Memorial Lecture #ACR22 @RheumNow @ACRheum insights by a humble #SSc leader 🙏🏻 https://t.co/M82p6DwZ6Q
Dr. Rachel Tate uptoTate
3 years 1 month ago
AURORA 2 data VOC-treated pts w/ pure and mixed Class V lupus nephritis saw reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Abs 0355 #ACR22 @RheumNow https://t.co/eHVLDCcti8 https://t.co/jbuiOSqqsa
Julian Segan JulianSegan
3 years 1 month ago
Targeting MRI remission in RA, specifically targeting osteitis, did not confer benefit over clinical T2T over 2 years. Maybe our clinical examination is not so bad afterall @steverheum_hall
@RheumNow ABST0890 #ACR22
https://t.co/8nUjWQONyk https://t.co/xGzZNLiJ7U
Richard Conway RichardPAConway
3 years 1 month ago
Meng MA of risk of tapering MTX from combo with bDMARD/tsDMARD in RA in remission. RR 0.90 (95% CI 0.84, 0.97) for maintaining remission over maximum 18 months. Authors conclude little risk to stopping - I disagree 10% is >0. @RheumNow #ACR22 Abstr#0916 https://t.co/9lJXdeVmpg https://t.co/CEV29Mc8uW
Dr. Rachel Tate uptoTate
3 years 1 month ago
> 50% of SLE pts showed activation of all 3 complement pathways. The most frequent patterns were normal CL, low AL, normal MBL; low CL & AL, normal MBL. Dz activity, not damage, assoc'd only w/low CL and AL, and normal MBL. Abs 0317 #ACR22 @RheumNow https://t.co/nXtuZCfKDI
Richard Conway RichardPAConway
3 years 1 month ago
Leng et al. 52 week results tocilizumab biosimilar vs originator in RA. Shocker, it's the same. @RheumNow #ACR22 Abstr#0917 https://t.co/5JAoGBRzUi https://t.co/7zCUNcdzbp
Dr. Rachel Tate uptoTate
3 years 1 month ago
Proliferative LN assoc'd w/ higher risk of IFTA progression, suggesting that glomerular damage is one of the major drivers of IFTA progression in SLE. Abs 0319 #ACR22 @RheumNow https://t.co/CgdXhDBk3e https://t.co/AOZ1DnH6Sk
Mike Putman EBRheum
3 years 1 month ago
Package insert for avacopan has a lot of monitoring requirements, including liver risk, but that seems to be relatively small (2 events per 100 pt-yrs vs pred). Other risks actually favorable as compared to pred
How are others monitoring LFTs?
#ACR22 @RheumNow #1077 https://t.co/VFHCpkQMWN
Poster Hall